KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with toripalimab in patients with advanced melanoma.
Melanoma
DRUG: KD6001|DRUG: Toripalimab
Number of Participants with Dose Limiting Toxicities (DLTs), DLTs will be assessed during the dose-escalation phase and are defined as the following treatment-related adverse events occurring within a total of 21 days after the first trial administration., Up to Day 21|The incidence and safety profile of participants with adverse events (AEs), serious adverse events(SAE), and immune-related adverse event(irAE), Evaluate the adverse events (AE) according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 (NCI CTCAE 5.0)., Baseline to study completion up to 2 years|Maximum tolerated dose (MTD), The maximum tolerated dose (MTD) of KD6001 combined with toripalimab, Up to Day 21|Recommended Phase II dose (RP2D), Recommended Phase 2 dose (RP2D) of KD6001 combined with toripalimab, Up to Day 21
The antitumor activity of KD6001 in combination with Toripalimab measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST 1.1, Number of participants with response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria and modified RECIST 1.1, Baseline to study completion up to 2 years|The PK profile of KD6001 in combination with Toripalimab, Drug concentration of individual subject at different time points after administration; Pharmacokinetic parameters, Baseline to study completion up to 2 years|The immunogenicity of KD6001 in combination with Toripalimab, Including the incidence of ADA positive. For ADA positive patients, the incidence of neutralizing antibody (NAB) will be analyzed., Baseline to study completion up to 2 years
This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with toripalimab in patients with advanced melanoma.